Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, Karolinska Institutet, Huddinge, Sweden.
Stockholms Sjukhem Foundation, Stockholm, Sweden.
Brain Behav. 2018 Sep;8(9):e01081. doi: 10.1002/brb3.1081. Epub 2018 Aug 22.
Knowledge of the relationships between patient-reported and performance-based walking measures in Parkinson's disease (PD) should inform clinical decision-making. The Walk-12G reliably captures perceived walking difficulties but has not been compared to performance-based walking in laboratory or free-living settings or across different groups.
To investigate the relationship between patient-reported walking difficulties (Walk-12G) and performance-based walking in laboratory and free-living conditions and to determine whether the Walk-12G can distinguish between the subgroups, (i) people with/without PD and (ii) mild/moderate disease stages.
Forty-seven people without and 49 people with PD (Hoehn and Yahr stage II and III) were assessed in relation to patient-reported walking difficulties (Walk-12G scale); spatiotemporal gait characteristics (Pace; Rhythm; Asymmetry; Variability; and Postural control) using a laboratory-based electronic walkway; and walking behavior (mean steps/day and minutes of brisk walking/day) using accelerometers in free-living conditions.
The Walk-12G correlated moderately with the spatiotemporal domain step velocity (r = -0.46) and walking behavior, measured as mean steps/day (r = -0.46). Weaker correlations were observed for step length and minutes spent in brisk walking (r = -0.36 and r = -0.35, respectively). Poor correlations were observed for all other spatiotemporal domains. The Walk-12G could distinguish between people with and without PD (Effect size, r = 0.82) and between those at mild/moderate disease stages (r = 0.34).
Perceived walking difficulties showed weak to moderate associations with performance-based measures of walking in mild-moderate PD. As the strongest associations were observed for step velocity and walking behavior, targeting these specific gait aspects could improve perceived walking difficulties in daily life.
了解帕金森病(PD)患者报告的和基于表现的步行测量之间的关系,应该有助于临床决策。Walk-12G 能够可靠地捕捉到感知到的步行困难,但尚未在实验室或自由生活环境中或在不同组之间与基于表现的步行进行比较。
调查实验室和自由生活条件下患者报告的步行困难(Walk-12G)与基于表现的步行之间的关系,并确定 Walk-12G 是否可以区分以下亚组:(i)有无 PD 的人群,以及(ii)轻度/中度疾病阶段的人群。
评估了 47 名无 PD 和 49 名 PD 患者(Hoehn 和 Yahr 分期 II 和 III)的步行困难(Walk-12G 量表);使用基于实验室的电子步道进行时空步态特征(步速、节奏、不对称、变异性和姿势控制);使用加速度计在自由生活条件下进行步行行为(每日平均步数和每日轻快步行分钟数)。
Walk-12G 与时空域步速(r=-0.46)和步行行为(每日平均步数,r=-0.46)中度相关。与步长和轻快步行时间(r=-0.36 和 r=-0.35)的相关性较弱。与所有其他时空域的相关性较差。Walk-12G 可以区分有无 PD 的人群(效应量,r=0.82)以及疾病轻度/中度阶段的人群(r=0.34)。
在轻度至中度 PD 中,感知到的步行困难与基于表现的步行测量之间存在弱到中度的关联。由于最强的关联是观察到的步速和步行行为,因此针对这些特定的步态方面,可能会改善日常生活中的感知步行困难。